

NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

Myeloma

Eighth Guideline Development Group (GDG) meeting

26th January 2015

Cancer Research UK Clinical Trials Unit, Birmingham University

GROUP MEMBERSHIP & ACTION LIST

GDG Members	
Curly Morris (CM)	Monica Morris (MM)
Guy Pratt (GP)	Sam Ahmedzai (SA)
Matthew Jenner (MJ)	Nicola Montacute (NMo)
Matthew Streetly (MS)	Alan Chant (ACh)
John Snowden (JS)	Andrea Guy (AG)
Nicola Mulholland (NM)	Lesley Roberts (LR)
Hamdi Sati (HS)	
NCC-C staff	
Angela Bennett (AB)	Katrina Blears (KB)
James Hawkins (JH)	Angharad Morgan (AM)
Matthew Prettyjohns (MP)	
NICE staff	
Katie Perryman-Ford (KPF)	Katherine McAllister (KMc)
Apologies	
Jane Woodward (JW)	
Attending	
David Wilson (DW)	

REPORTS OF DISCUSSIONS AT THE MEETING

1. Introductions

CM welcomed everyone to the 8th meeting of the Myeloma GDG.

2. Declarations of Interest

The following declarations of interest were declared:

- SA declared that he has been appointed by the Royal College of Physicians to be their Clinical Lead for the National Care of the Dying audit. This is a funded post and the role is to advise and lead the RCP audit team in designing a new format for the National Care of the Dying audit, overseeing its application and helping RCP to announce and disseminate the results. This was classified as personal pecuniary non-specific meaning that SA can participate in discussion on all topics as it is not specific to myeloma.

The GDG were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that the necessary action can be taken.

3. Discussions

The GDG discussed the clinical and health economic evidence for topic L3.

The GDG discussed the evidence and agreed the recommendations and LETR tables for topic G.

The GDG reviewed the edited LETR tables for topics L1 and P.

4. Close of meeting

CM thanked the GDG for their input to the meeting, reminded them that the next meeting would be on **Tuesday 10th March 2015**, starting at 10.30 in the **Cancer Research UK Clinical Trials Unit, Birmingham University**.